Anti-OX40 Antibody in Head and Neck Cancer Patients
Status:
Active, not recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of the anti-OX40 antibody, MEDI6469, given
prior to surgery in patients with advanced head and neck squamous cell carcinoma.